At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Age-Related Changes in Nanoparticle Albumin Bound (Nab) Paclitaxel Pharmacokinetics and Pharmacodynamics
In Brief
A Phase 2 clinical trial evaluating paclitaxel albumin-stabilized nanoparticle formulation, pharmacological study, and 5 other interventions for Breast Cancer. Active but no longer recruiting, targeting 40 participants across 2 sites.
Signals
Detailed Summary
RATIONALE: Gathering information from patients of different ages receiving paclitaxel albumin-stabilized nanoparticle formulation for metastatic breast cancer may help doctors understand how the age of the patient changes the way the drug works. PURPOSE: This phase II trial is studying how well paclitaxel albumin-stabilized nanoparticle formulation works in treating patients of different ages with metastatic breast cancer.
Study Details
Timeline
Arms & Interventions
Interventions
100 mg/m2 3 weeks on 1 week off
Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy